Expertise in
27
conditions

Dr. Jeffrey M. Kamradt

Hematology | Oncology
Hartford Healthcare Medical Group
85 Retreat Ave, 
Hartford, CT 
Offers Telehealth
Expertise in
27
conditions
Hartford Healthcare Medical Group
85 Retreat Ave, 
Hartford, CT 

Overview

Jeffrey Kamradt is a Hematologist and an Oncologist practicing medicine in Hartford, Connecticut.

Dr. Kamradt is highly rated in 27 conditions, according to our data. His clinical expertise encompasses Prostate Cancer, Familial Prostate Cancer, Clear Cell Sarcoma, and WT1-Related Wilms Tumor Syndromes.

He is actively involved in clinical research, co-authoring 5 peer reviewed articles and participating in 3 clinical trials.

Specialties

Hematology
Oncology

Licenses

Internal Medicine in CT

Hospital Affiliations

Hartford Hospital
The Hospital Of Central Connecticut
Midstate Medical Center
William W Backus Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 4 Less Insurance Carriers -

Locations

Hartford Healthcare Medical Group
85 Retreat Ave, Hartford, CT 06106

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Biological, Procedure
Study Drug: Nivolumab
Study Phase: Phase 3
A Phase II Study of Gemcitabine Plus Cisplatin Chemotherapy in Patients With Muscle-invasive Bladder Cancer With Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations
A Phase II Study of Gemcitabine Plus Cisplatin Chemotherapy in Patients With Muscle-invasive Bladder Cancer With Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Procedure, Drug, Biological, Other
Study Drugs: Gemcitabine, Cisplatin, Pegfilgrastim
Study Phase: Phase 2
A Pilot Safety Study and Single Arm Phase II Study of Gemcitabine and Cisplatin With Atezolizumab (MPDL3280A) in Patients With Metastatic and Muscle Invasive Bladder Cancer, Respectively
A Pilot Safety Study and Single Arm Phase II Study of Gemcitabine and Cisplatin With Atezolizumab (MPDL3280A) in Patients With Metastatic and Muscle Invasive Bladder Cancer, Respectively
Enrollment Status: Active_not_recruiting
Publish Date: January 07, 2026
Intervention Type: Drug
Study Drugs: Atezolizumab, Gemcitabine, Cisplatin
Study Phase: Phase 1/Phase 2
View 2 Less Clinical Trials

5 Total Publications

Neoadjuvant Chemotherapy for High-risk Localized Upper Tract Urothelial Carcinoma: Final Long-term Outcomes from a Phase 2 Clinical Trial and an Expanded Cohort.
Neoadjuvant Chemotherapy for High-risk Localized Upper Tract Urothelial Carcinoma: Final Long-term Outcomes from a Phase 2 Clinical Trial and an Expanded Cohort.
Journal: European urology
Published: April 22, 2025
Similar Doctors
Expertise in
11
conditions
Dr. Farzana D. Pashankar
Hematology | Oncology
Expertise in
11
conditions
Dr. Farzana D. Pashankar
Hematology | Oncology
Referral may be required

Yale New Haven Hospital

20 York St, 
New Haven, CT 
 (33.7 miles away)
203-785-4081
Languages Spoken:
English
See accepted insurances

Farzana Pashankar is a Hematologist and an Oncologist practicing medicine in New Haven, Connecticut. Dr. Pashankar is highly rated in 11 conditions, according to our data. Her clinical expertise encompasses Germ Cell Tumor, Teratoma of the Mediastinum, Testicular Yolk Sac Tumor, Bone Marrow Aspiration, and Bone Marrow Transplant.

Expertise in
22
conditions
Dr. Harriet Kluger
Hematology | Oncology
Expertise in
22
conditions
Dr. Harriet Kluger
Hematology | Oncology
Referral may be required

Smilow Cancer Hospital

35 Park St, # Np8, 
New Haven, CT 
 (33.7 miles away)
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Harriet Kluger is a Hematologist and an Oncologist practicing medicine in New Haven, Connecticut. Dr. Kluger is highly rated in 22 conditions, according to our data. Her clinical expertise encompasses Melanoma, Merkel Cell Carcinoma, Renal Cell Carcinoma (RCC), Metastatic Brain Tumor, and Nephrectomy.

Expertise in
15
conditions
Dr. Michael S. Isakoff
Hematology | Oncology | Pediatrics
Expertise in
15
conditions
Dr. Michael S. Isakoff
Hematology | Oncology | Pediatrics
Referral may be required

CCMC - Hematology

282 Washington St, 
Hartford, CT 
 (0.1 miles away)
860-545-9630
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Michael Isakoff is a Hematologist and an Oncologist practicing medicine in Hartford, Connecticut. Dr. Isakoff is highly rated in 15 conditions, according to our data. His clinical expertise encompasses Osteosarcoma, Adult Soft Tissue Sarcoma, Ewing Sarcoma, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Isakoff is board certified in American Board Of Pediatrics and American Board Of Pediatrics, Pediatric Hematology & Oncology, Pediatric Hematology Oncology . Dr. Isakoff is currently accepting new patients.

Frequently Asked Questions about Dr. Jeffrey M. Kamradt

How do I make an appointment with Dr. Jeffrey M. Kamradt?

You can book an appointment with Dr. Jeffrey M. Kamradt by calling their office at 860-972-4183. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Jeffrey M. Kamradt a top-rated expert for Prostate Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Jeffrey M. Kamradt is classified as an Distinguished expert for Prostate Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Jeffrey M. Kamradt specialize in?

While Dr. Jeffrey M. Kamradt is a Hematology, they have specific expertise in Prostate Cancer, Familial Prostate Cancer, and Clear Cell Sarcoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Jeffrey M. Kamradt participate in research or clinical trials?

Yes. Dr. Jeffrey M. Kamradt has published 5 articles and abstracts on conditions like Prostate Cancer. You can view a list of Dr. Jeffrey M. Kamradt's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Jeffrey M. Kamradt accept my insurance?

Dr. Jeffrey M. Kamradt accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 860-972-4183 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kamradt's expertise for a condition
ConditionClose
    View All 11 Distinguished Conditions
    View All 16 Advanced Conditions
    View All 73 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile